TNFRSF11B and breast carcinoma: These results indicate that chemerin treatment blocks the increase in the RANKL/OPG ratio in osteoblastic cells stimulated with conditioned medium from MDA-MB-231 breast cancer cells, thereby preventing RANKL-induced osteoclastogenesis and breast cancer cell-associated bone loss.